The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Maryland has become one of the first states to set a price cap on Ozempic through its prescription drug affordability board. This move could reshape how GLP-1 medications are priced across the country, and it matters whether you're currently on semaglutide or considering starting it.
Research confirms that people taking GLP-1 medications like semaglutide and tirzepatide face a specific and frustrating form of social stigma. This article breaks down what the science shows, why this stigma exists, and practical ways to protect your mental health and stay committed to your treatment plan.
Social media is flooded with "natural Mounjaro" drink recipes claiming to mimic the weight loss effects of tirzepatide. Before you blend anything, here's what the science says about these viral concoctions, why they fall short, and what your real options look like.
Eli Lilly is advancing a new oral weight loss drug that may deliver stronger results than both Wegovy and its own Zepbound. Here's what the clinical data shows so far, what it means for patients currently on GLP-1 medications, and how to think about your options while this drug moves through trials.
When a billionaire investor says eBay "needs to be on Ozempic," it signals how deeply semaglutide has entered the cultural conversation. But for real patients, the more important question is what this attention means for access, cost, and treatment options in 2025 and beyond.
Novo Nordisk is working to rebuild momentum around Wegovy with new clinical data and a growing drug pipeline. For patients considering semaglutide or comparing GLP-1 options, these developments have real implications for access, cost, and future treatment choices. Here's what you need to know.
Generic versions of semaglutide (the active ingredient in Ozempic) are becoming available in several countries, but U.S. patients face a longer wait due to patent protections. Here is what that means for your wallet, your treatment options, and what you can realistically do today.
FDA Commissioner Marty Makary is stepping down, with Kyle Diamantas stepping in as acting commissioner. For patients on GLP-1 medications like semaglutide or tirzepatide, this kind of transition raises real questions about drug approvals, compounding policy, and access. Here's what you actually need to know.
